{
    "nct_id": "NCT05036291",
    "official_title": "A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered As Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors",
    "inclusion_criteria": "1. males or females of any race>(=)18 years age.\n2. Histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are without standard treatment options (part 1).\n\n   Pathologically confirmed locally advanced or metastatic solid tumors with KRAS G12C mutation as determined by a test that has been approved by FDA or local health authority (part 2&3).\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Life expectancy>(=)12 weeks.\n5. Adequate organ and marrow function.\n6. Measurable or evaluable disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.\n2. Toxicities from previous anti-cancer therapy that have not recovered as required.\n3. Brain metastatic disease, spinal cord compression, or leptomeningeal carcinomatosis.\n4. Active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV):\n5. Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while in this study or within 3 months after the last dose.\n6. Male subjects who plan to father a child while enrolled in the study or within 3 months after the last dose.\n7. Received prior treatment with a PIM kinase inhibitor.",
    "miscellaneous_criteria": ""
}